Related Experiment Video
Updated: May 18, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Telaprevir: pharmacokinetics and drug interactions
Varun Garg1, Robert S Kauffman, Maria Beaumont
1Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA. varun_garg@vrtx.com
Telaprevir significantly boosts sustained virological response for Hepatitis C Virus (HCV) when combined with pegylated interferon and ribavirin. This protease inhibitor shows good oral absorption and requires no dose adjustment for renal or mild liver impairment.
Area of Science:
- Hepatology
- Pharmacology
- Virology
Background:
- Hepatitis C Virus (HCV) infection is a major global health concern.
- HCV NS3/4A protease inhibitors are crucial in antiviral therapy.
- Pegylated interferon and ribavirin are standard treatments, but response rates can be improved.
Purpose of the Study:
- To review the pharmacokinetic profile of telaprevir.
- To examine the drug interaction potential of telaprevir.
- To assess telaprevir's efficacy in combination therapy for HCV.
Main Methods:
- Review of published pharmacokinetic and clinical trial data for telaprevir.
- Analysis of telaprevir's metabolism and excretion pathways.
- Evaluation of telaprevir's interactions with cytochrome P450 3A and P-glycoprotein.
Main Results:
- Telaprevir, an HCV NS3/4A protease inhibitor, enhances sustained virological response when combined with pegylated interferon and ribavirin.
- Telaprevir exhibits good oral bioavailability, further improved with food.
- No dose adjustments are necessary for mild to severe renal or mild hepatic impairment.
Conclusions:
- Telaprevir is an effective oral antiviral agent for HCV treatment.
- Understanding telaprevir's pharmacokinetic and drug interaction profile is vital for clinical use.
- Telaprevir offers a valuable therapeutic option for improving HCV treatment outcomes.
More Related Videos
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
07:18High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing
Published on: January 22, 2019
Related Concept Videos
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Pharmacokinetics: Drug–Drug Interactions
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Drug toxicity: Drug–Drug Interaction
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Pharmacokinetics in Pediatric Patients: Drug Excretion